Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2006-07-24
2010-02-09
Tate, Christopher R (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S093100, C424S400000, C435S325000
Reexamination Certificate
active
07658915
ABSTRACT:
This invention provides methods of increasing blood flow to tissue in a subject in need thereof, methods of regenerating tissue in a subject, methods of treating diseased tissue in a subject, methods of forming new blood vessels in tissue and new tissue, such as myocardial tissue, in a subject in need thereof, methods of increasing angiogenesis in diseased tissue in a subject, and methods of preventing heart failure in a subject, which methods comprise: a) isolating autologous mononuclear cells from the subject; b) selecting from the isolated autologous mononuclear cells of step (a) lineage negative (Lin−) mononuclear cells; and c) transplanting locally into or adjacent to the tissue an effective amount of the Lin−autologous mononuclear cells, resulting in formation of new blood vessels in the tissue and formation of new tissue. Additional methods provided for such uses further select from the isolated autologous mononuclear cells of step (a) lineage negative (Lin−) mononuclear cells a subset of Lin−mononuclear side population (SP) cells and transplant locally into or adjacent to the tissue an effective amount of the Lin−SP cells. In other aspects, methods using tissue other than mononuclear cells for these uses are provided, which comprise (a) obtaining a cell suspension from the tissue or a second tissue of the subject; (b) selecting from the cell suspension step (a) side population (SP) cells; and (c) transplanting locally into or adjacent to the tissue an effective amount of the SP cells, resulting in formation of new blood vessels in the tissue and formation of new tissue.
REFERENCES:
patent: 2002/0061587 (2002-05-01), Anversa
patent: 2002/0098167 (2002-07-01), Anversa et al.
patent: 2003/0003085 (2003-01-01), Kunkel et al.
patent: 2003/0054973 (2003-03-01), Anversa
patent: WO 00/17657 (2000-03-01), None
patent: WO 01/19379 (2001-03-01), None
patent: WO 01/27245 (2001-04-01), None
Anversa et al., “Myocyte Growth and Cardiac Repair”, J. Mol. Cell Cardiol., vol. 34, 2002, pp. 91-105.
Arbatli et al., “Cardioscopy and Robotic Assistance for the Diagnosis of Intraventricular Endocarditis”, J. Heart Valve Dis., vol. 10, No. 5, Sep. 2001, pp. 686-688.
Bao et al., “Intramyocardial Delivery of FGF2 in Combination With Frequency Transmyocardial Revascularization”, Catheterization and Cardiovascular Interventions, vol. 53, 2001, pp. 429-434.
Grossman et al., “Incomplete Retention After Direct Myocardial Injection,” Catheterization and Cardiovascular Interventions, vol. 55, 2002, pp. 392-397.
Hierlihy et al., “The post-natal heart contains a myocardial stem cell population,” FEBS Letters, vol. 530, 2002, pp. 239-243.
Koke et al. “Release of lactate dehydrogenase during isolation of adult rat heart cells,” Cytobios, vol. 29, 1980, pp. 183-189.
Urbanek et al., “Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy,” PNAS, vol. 100, No. 18, Sep. 2, 2003, pp. 10440-10445.
Urbanek et al., “Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure,” PNAS, vol. 102, No. 24, Jun. 14, 2005, pp. 8692-8697.
Young, “Preparation of Isolated Cells from Rat Heart,” Experientia, vol. 32, 1976, pp. 1389-1390.
Goodell M., “Blood,” The Journal of the American Society of Hematology, vol. 94, No. 8, (Oct. 15, 1999), 2545-2547.
Goodell M. et al., “Isolation and Functional Properties of Murine Hematopoietic Stem Cells that are Replicating In Vivo,” The Journal of Experimental Medicine, The Rockefeller University Press, vol. 183, (Apr. 1996), pp. 1797-1806.
Gussoni E. et al., “Dystrophin expression in the mdx mouse restored by stem cell transplantation,” Nature, vol. 401, (Sep. 23, 1999), pp. 390-394.
Huss R., “CD34 stem cells as the earliest precursors of hematopoietic progeny,” Experimental Hematology, vol. 26, (1998) pp. 1022-1023.
Jackson K. et al., “Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells,” The Journal of Clinical Investigation, vol. 107, No. 11, (Jun. 2001), pp. 1395-1402.
Kamihata H. et al., “Implantation of Bone Marrow Mononuclear Cells Into Ischemic Myocardium Enhances Collateral Perfusion and Regional Function via Side Supply of Angioblasts, Angiogenic Ligands, and Cytokines,” Circulation (2001) pp. 1046-1052, vol. 104.
Kocher A.A. et al., “Neovascularization of ischemic myocardium by human bone marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function,” Nature Medicine, vol. 7, No. 4 (Apr. 2001), pp. 430-436.
Orlic D. et al., “Bone marrow cells regenerate infarcted myocardium”, Nature, vol. 410, (Apr. 5, 2001), pp. 701-705.
Orlic D. et al., “PNAS USA 98”, (2001), pp. 10344-10349.
Otani A. et al., “Bone Marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis”, Nature Medicine, vol. 8, No. 9, (Sep. 2002), pp. 1004-1010.
Sato T. et al., “Reversible Expression of CD34 by Murine Hematopoietic Stem Cells”, Blood, vol. 94, No. 8 (Oct. 15, 1999, pp. 2548-2554.
Steinberg D., “Precursor Cells to the Rescue”, The Scientist (Nov. 27, 2000), p. 24.
Steinberg D., “Stem Cells Tapped to Replenish Organs”, The Scientist (Nov. 27, 2000), pp. 20-21, 24.
Zanjani E. D., “Human bone marrow CD34−cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+cell”, Experimental Hematology, vol. 26, (1998), pp. 353-360.
Liu, et al., “Phenotypic and in vitro characterization of Hoechst 33342 side population in umbilical cord blood”, Blood, vol. 96, No. 11, part 1, Nov. 16, 2000, Abstract.
Mahmud Nadim et al., “The hematopoietic cellular potential of primate skeletal muscle cells”, Blood, vol. 96, No. 11, part 1, Nov. 16, 2000, Abstract.
Josefsen et al., “Hematopoietic side population (SP) cells are present in highly purified human CD34+ cells from peripheral blood progenitor cells (PBPC),” Blood, vol. 98, No. 11, part 2, Nov. 16, 2001, Abstract.
Jackson et al., PNAS 96(25): 14482-14486 (Dec. 7, 1999).
Jackston et al., Journal of Cellular Biochemistry Supplement 38:1-6 (May 16, 2002).
Orlic et al., Annalsof the New York Academy of Sciences 938: 221-230 (Jun. 2001).
Orlic, International Journal of Hematology, 76 Suppl. 1: 144-145 (Aug. 2002).
Boston Scientific Scimed Inc.
Kenyon & Kenyon LLP
Kosar Aaron J
Tate Christopher R
LandOfFree
Selected cell delivery for heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selected cell delivery for heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selected cell delivery for heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4231324